246 related articles for article (PubMed ID: 27602604)
21. h-Caldesmon expression effectively distinguishes endometrial stromal tumors from uterine smooth muscle tumors.
Nucci MR; O'Connell JT; Huettner PC; Cviko A; Sun D; Quade BJ
Am J Surg Pathol; 2001 Apr; 25(4):455-63. PubMed ID: 11257619
[TBL] [Abstract][Full Text] [Related]
22. [A clinical analysis of 153 uterine sarcomas].
Bai P; Sun J; Chao H
Zhonghua Fu Chan Ke Za Zhi; 1997 Mar; 32(3):163-7. PubMed ID: 9596892
[TBL] [Abstract][Full Text] [Related]
23. Molecular characteristics of uterine sarcomas.
Davidson B; Micci F
Expert Rev Mol Diagn; 2017 May; 17(5):515-522. PubMed ID: 28335657
[TBL] [Abstract][Full Text] [Related]
24. [Endometrial and other rare uterine sarcomas : Diagnostic aspects in the context of the 2020 WHO classification].
Mayr D; Horn LC; Hiller GGR; Höhn AK; Schmoeckel E
Pathologe; 2022 May; 43(3):183-195. PubMed ID: 35362728
[TBL] [Abstract][Full Text] [Related]
25. Role of the Immunohistochemical ZEB1 Expression in Uterine Mesenchymal Neoplasms.
Çelik M; Çelik ZE
Int J Surg Pathol; 2022 Aug; 30(5):520-527. PubMed ID: 34994578
[TBL] [Abstract][Full Text] [Related]
26. High-grade Endometrial Stromal Sarcoma: Morphologic and Clinical Features, the Role of Immunohistochemistry and Fluorescence in Situ Hybridization in Diagnosis.
Alkanat NE; Uner A; Usubutun A
Int J Surg Pathol; 2023 Aug; 31(5):521-531. PubMed ID: 35506912
[No Abstract] [Full Text] [Related]
27. Epithelioid endometrial and endometrioid stromal tumors: a report of four cases emphasizing their distinction from epithelioid smooth muscle tumors and other oxyphilic uterine and extrauterine tumors.
Oliva E; Clement PB; Young RH
Int J Gynecol Pathol; 2002 Jan; 21(1):48-55. PubMed ID: 11781523
[TBL] [Abstract][Full Text] [Related]
28. [Prognostic factors of mesenchymal and mixed tumors of uterus].
Spacek J; Laco J; Petera J; Jílek P; Krepinská E; Rezác A; Stipl S
Ceska Gynekol; 2009 Aug; 74(4):292-7. PubMed ID: 20564985
[TBL] [Abstract][Full Text] [Related]
29. Morcellating uterine mesenchymal tumors: The pathologist's view.
Pavlakis K; Messini I; Yiannou P; Gavresea T; Chrysanthakis D; Hilaris G; Panoskaltsis T
J Obstet Gynaecol Res; 2017 Mar; 43(3):580-586. PubMed ID: 28120430
[TBL] [Abstract][Full Text] [Related]
30. Uterine epithelioid leiomyosarcoma with c-kit expression and YWHAE gene rearrangement: a case report of a diagnostic pitfall of uterine sarcoma.
Kubo T; Sugita S; Wada R; Kikuchi N; Iwasaki M; Ito Y; Sugawara T; Fujita H; Emori M; Tanaka R; Hirano H; Saito T; Hasegawa T
Diagn Pathol; 2017 Mar; 12(1):26. PubMed ID: 28288693
[TBL] [Abstract][Full Text] [Related]
31. Patterns of Chromosomal Abnormalities that Can Improve Diagnosis of Uterine Smooth Muscle Tumors.
Holzmann C; Markowski DN; VON Leffern I; Löning T; Bullerdiek J
Anticancer Res; 2015 Dec; 35(12):6445-56. PubMed ID: 26637855
[TBL] [Abstract][Full Text] [Related]
32. [Immunohistochemical study of endometrial stromal sarcoma and smooth-muscle tumors of the uterus].
Farah-Klibi F; Ben Hamouda S; Ben Romdhane S; Sfar R; Koubaa A; Ben Jilani S; Zermani R
J Gynecol Obstet Biol Reprod (Paris); 2008 Sep; 37(5):457-62. PubMed ID: 18565690
[TBL] [Abstract][Full Text] [Related]
33. [Mesenchymal and mixed uterine tumors : Current overview and practical aspects].
Lax SF
Pathologe; 2019 Feb; 40(1):36-45. PubMed ID: 30694356
[TBL] [Abstract][Full Text] [Related]
34. The Clinicopathological Study of 21 Cases With Uterine Smooth Muscle Tumors of Uncertain Malignant Potential: Centralized Review Can Purify the Diagnosis.
Basaran D; Usubutun A; Salman MC; Narin MA; Boyraz G; Turkmen O; Comert Kimyon G; Karalok A; Bulbul D; Turan T; Ozgul N; Yuce K
Int J Gynecol Cancer; 2018 Feb; 28(2):233-240. PubMed ID: 29303932
[TBL] [Abstract][Full Text] [Related]
35. Patterns of bone morphogenetic protein-2 expression in smooth muscle tumors of the uterine corpus and other uterine tissues.
Fadare O; Renshaw IL; Liang SX
Appl Immunohistochem Mol Morphol; 2011 Jul; 19(4):352-9. PubMed ID: 21285872
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical and selected genetic reflex testing of all uterine leiomyosarcomas and STUMPs for ALK gene rearrangement may provide an effective screening tool in identifying uterine ALK-rearranged mesenchymal tumors.
Ptáková N; Miesbauerová M; Kosťun J; Grossmann P; Šidlová H; Pavelka J; Presl J; Alaghehbandan R; Bouda J; Ondič O
Virchows Arch; 2018 Nov; 473(5):583-590. PubMed ID: 30116888
[TBL] [Abstract][Full Text] [Related]
37. Microsatellite instability in uterine sarcomas.
Amant F; Dorfling CM; Dreyer L; Vergote I; Lindeque BG; Van Rensburg EJ
Int J Gynecol Cancer; 2001; 11(3):218-23. PubMed ID: 11437928
[TBL] [Abstract][Full Text] [Related]
38. [Sarcomas and mixed mesodermal tumors of the uterus].
Günthert AR
Ther Umsch; 2011 Oct; 68(10):559-64. PubMed ID: 21968895
[TBL] [Abstract][Full Text] [Related]
39. Uterine Mesenchymal Tumors: Update on Classification, Staging, and Molecular Features.
Parra-Herran C; Howitt BE
Surg Pathol Clin; 2019 Jun; 12(2):363-396. PubMed ID: 31097109
[TBL] [Abstract][Full Text] [Related]
40. Analysis of allelic loss as an adjuvant tool in evaluation of malignancy in uterine smooth muscle tumors.
Esposito NN; Hunt JL; Bakker A; Jones MW
Am J Surg Pathol; 2006 Jan; 30(1):97-103. PubMed ID: 16330948
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
